Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 12, 2003 - Issue 4
Submit an article Journal homepage
201
Views
42
CrossRef citations to date
0
Altmetric
Drug Evaluation

The therapeutic potential of costimulatory blockade with CTLA4Ig in rheumatoid arthritis

Paul Emery Academic Unit of Musculoskeletal Disease, Department of Rheumatology, 1st Floor, Leeds General Infirmary, Great George Street, Leeds, LS1 3EX, UK
Pages 673-681 | Published online: 02 Mar 2005

Bibliography

  • ABDELATY EM, SCHUMACHER HRJr: New therapeutic approaches for rheumatoid arthritis. Int..1. Clin. Pract. (1999) 53(7):535–539.
  • BENDTSEN P, HORNQUIST JO: Change and status in quality of life in patients with rheumatoid arthritis. Qual Life Res. (1992) 1(5):296–305.
  • MASON JH, VVEENER JL, GERTMAN PM, MEENAN RF: Health status in chronic disease: a comparative study of rheumatoid arthritis. j. Rheumatol (1983) 10(5):763–768.
  • STRAND V, KEYSTONE E, BREEDWALD F: Biologic agents for the treatment of rheumatoid arthritis. Rheum. Dis. Clin. North Am. (1996) 22:117–132.
  • •Good overview of biological therapy in RA.
  • MORELAND LW, HECK LW Jr, SULLIVAN W et al.: New approaches to the therapy of autoimmune diseases: rheumatoid arthritis as a paradigm. Am. .1. Med. Sci. (1993) 305:40–51.
  • •Review and role of RA as a paradigm.
  • BATHON JM, MARTIN RW, FLEISCHMANN RIVI et al: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl. Med. (2000) 343:1586–1593.
  • •Landmark study of etanercept in early disease.
  • LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al.: Infliximab and methrotrexate in the treatment of rheumatoid arthritis. N Engl. I Med. (2000) 343:1594–1602.
  • •Landmark study of inflizimab and methotrexate on radiological outcome.
  • BRESNIHAN B, ALVARO-GRACIA JM, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritic Rheum. (1998) 41:2196–2204.
  • ST CLAIR EW: Tides of inflammation: impact of biologics. Rheumatol. (2002) 65(Suppl.):22–26.
  • MCINNES TB: Rheumatoid arthritis: from bench to bedside. Rheum. Dis. Clin. North Am. (2001) 27(2):373–387.
  • GRACIE JA, LEUNG BP, MCINNES TB: Novel pathways that regulate tumour necrosis factor-alpha production in rheumatoid arthritis. Curr: Opin. Rheumatol (2002) 14(3):270–275.
  • ROMAS E, GILLESPIE MT, MARTIN TJ: Involvement of receptor activator of NFicB ligand and tumour necrosis factor-a in bone destruction in rheumatoid arthritis. Bone (2002) 30(2):340–346.
  • LANCHBURY JS: The HLA association with rheumatoid arthritis. Clio. Exp. Rheumatol (1992) 10:301–304.
  • PANAYI GS, CORRIGALL VM, PITZALIS C: Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. Rheum. Dis. Clio. North Am. (2001) 27(2):317–334.
  • ENDO H, AKAHOSHI T, TAKAGISHI K et al.: Experimental arthritis induced by continuous infusion of IL-8 into rabbit knee joints. Lymphokine Cytokine Res. (1991) 10:245.
  • KOCH AE, KUNKEL SL, HARLOW LA et al: Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. Clio. Invest. (1992) 90:772.
  • KOCH AE, KUNKEL SL, HARLOW LA et al: Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. Clio. Invest. (1994) 93:921.
  • KUNKEL SL, LUKACS N, KASAMA T et al: The role of chemokines in inflammatory joint disease. Leukoc. Biol. (1996) 59:6.
  • ROBINSON E, KEYSTONE EC, SCHALL TJ et al.: Chemokine expression in rheumatoid arthritis (RA): Evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta by synovial T cells. Clio. Exp. Immunol (1995) 101:398.
  • SZEKANECZ Z, STREITER PM, KUNKEL SL et al.: Chemokines in rheumatoid arthritis. Springer Semin. Immunopathol (1998) 20:115.
  • CHOY HSE, PANAYI GS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl. I Med. (2001) 344(12):907–916.
  • •Overview of cytokines in RA.
  • SAXNE T, PALLADINO MA Jr, HEINEGARD D et al.: Detection of tumour necrosis factor a but not tumour necrosis factor 13 in rheumatoid arthritis synovial fluid and serum. Arthritic Rheum. (1988) 31:1041–1045.
  • CHIKANZA IC, KINGSLEY G, PANAYI GS: Peripheral blood and synovial fluid monocyte expression of interleukin 1a13 and 113 during active rheumatoid arthritis. Rheumatol (1995) 22:600–606.
  • MOORE AR, NVAMURA H, LARBRE JP et al.: Cartilage degradation by polymorphonuclear leukocytes: M vitro assessment of the pathogenic mechanisms. Ann. Rheum. Dis. (1993) 52:27–31.
  • SHINGU M, NAGAI Y, ISAYAMA T et al.: The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clio. Exp. Immunol (1993) 94:145–149.
  • VAN SNICK J: Interleultin-6: an overview. Ann. Rev Immunol (1990) 8:253–278.
  • LUBBERTS E, JOOSTEN LA, OPPERS B et al.: IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. Immunol (2001) 167(2):1004–1013.
  • KLIMIUK PA, YANG H, GORONZY JJ et al.: Production of cytokines and metalloproteinases in rheumatoid synovitis is T cell dependent. Clio. Immunol (1999) 90:65–78.
  • KOTAKE S, UDAGAWA N, HAKODA M et al.: Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. (2001) 44:1003–1012.
  • BUKHARI M, LUNT M, HARRISON BJ et al.: Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum. (2002) 46(4):906–912.
  • WEYAND CM, BRYL E, GORONZY JJ: The role of T cells in rheumatoid arthritis. Arch. Immunol Ther. Exp. (War:0 (2000) 48 (5):429–435.
  • GIRASOLE G, PASSERI G, JILKA RL et al.: Interleukin-11: a new cytokine critical for osteoclast development. Clio. Invest. (1994) 93:1516–1524.
  • TEITELBAUM SL: Bone resorption by osteoclasts. Science (2000) 289:1504–1508.
  • LAM J, TAMESHITA S, BARKER JE et al.: TNF-a induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. Clio. Invest. (2000) 106:1481–1488.
  • KOBAYASHI K, TAKAHASHI N, JIMI E et al.: Tumour necrosis factor-alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/ RANKL-RANK interaction. I Exp. Med. (2000) 191:275–286.
  • FLEISCHMANN R, IQBAL I, NANDESH WAR P et al.: Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Sal (2002) 25(3):173–197.
  • BREEDVELD FC: Current and future management approaches for rheumatoid arthritis. Arthritis Res. (2002) 4\(Suppl. 2):516–521.
  • CRISCIONE LG, ST CLAIR EW: Tumour necrosis factor-alpha antagonists for the treatment of rheumatic diseases. Carr. Opin. Rheumatol (2002) 14(3):204–211.
  • WEISMAN MH: What are the risks of biologic therapy in rheumatoid arthritis? An update of safety. Rheumatol (2002) 29 (Suppl. 65):33–38.
  • WYSS-CORAY T, MAURI-HELLWEG D, BAUMANN K et al.: The B7 adhesion molecule is expressed on activated human T cells: functional involvement in T-T cell interactions. Ear: Immunol (1993) 23(9):2175–2180.
  • GOLDBERG D, MOREL P, CHATENOUD L et al.: Immunological effects of high dose administration of anit-CD4 antibody in rheumatoid arthritis patients. Autoimmun. (1991) 4:617–630.
  • CHOY EH, CHIKANZA IC, KINGSLEY GH et al.: Treatment of rheumatoid arthritis with single dose or weekly pulses of chimaeric anti-CD4 monoclonal antibody. Scand. Immunol (1992) 36:291–298.
  • WENDLING D, WIJDENES J, RACADOT E et al.: Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. Rheumatol (1991) 18:325–327.
  • LAFFERTY KJ, PRO WSE SJ, SIMEONOVIC CI: Immunobiology of tissue transplantation: a return to the passenger leukocyte concept. Ann. Rev Immunol (1983) 1:143–173.
  • MUELLER DL, JENKINS MK, SCHWARTZ RH: Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Ann. Rev. Immunol (1989) 7:445–480.
  • LINSLEY PS, BRADY W, GROSMAIRE L et al.: Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J. Exp. Med. (1991) 173:721–730.
  • KOULOVA L, CLARK EA, SHU G et al.:The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells. Exp. Med. (1991) 173:759–762.
  • YOUNG JW, KOUL OVA L, SOERGEL SA et al: The B7/BB1 antigen provides one of several costimulatory signals for the activation of CD4+ T lymphocytes by human blood dendritic cells M vitro. Clin. Invest. (1992) 90:229–237.
  • LINSLEY PS, GREEN IL, TAN P et al: Coexpression and functional cooperation of CTLA4 and CD28 on activated T lymphocytes. I Exp. Med. (1992) 176:1595–1604.
  • DAMLE NK, KLUSSMAN K, LEYTZE G et al.: Costimulation of T lymphocytes with intergrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7. Immunol (1994) 152:2682–2697.
  • •Document factors determining expression of CTLA4.
  • JENKINS MK, TAYLOR S, NORTON SD et al: CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. Immunol (1991) 147:2461–2466.
  • HARDING FA, MCARTHUR JG, GROSS JA et al.: CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature (1992) 356:607–609.
  • GIMMI CD, FREEMAN GI, GRIBBEN JG et al.: Human T-cell clonal anergy is induced by antigen presentation in the absence of B7 costimulation. Proc. Nati Acad. Sci. USA (1993) 90:6586–6590.
  • TAN P, ANASETTI C, HANSEN JA et al: Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1. Exp. Med. (1993) 177:165–173.
  • BOUSSIOTIS VA, FREEMAN GI, GRIFFIN JD et al: CD2 is involved in maintenance and reversal of human alloantigen-specific clonal anergy. Exp. Med. (1994) 180:1665–1673.
  • BOUSSIOTIS VA, BARBER DL, NAKARAI T et al.: Prevention of T cell anaergy by signaling through the 7 chain of the IL-2 receptor. Science (1994) 266:1039–1042.
  • PEARSON TC, ALEXANDER DZ, WINN KJ et al: Transplantation tolerance induced by CTLA4-Ig. Transplantation (1994) 57: 1701-1706.
  • SHIRAISHI T, YASUNAMI Y, TAKEHARA M et al.: Prevention of acute lung allograft rejection in rat by CTLA4IG. Am. .1 Transplant. (2002) 2:223–228.
  • LENSCHOW DJ, HO SC, SATTAR H et al.: Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. Exp. Med. (1995) 181:1145–1155.
  • FINCK B, LINSLEY PS, WOFSY D: Treatment of murine lupus with CTLA4Ig. Science (1994) 256:1225–1227.
  • PERRIN P, SCOTT D, QUIGLEY L et al.: Role of B7: CD28/CTLA-4 in the induction of chronic relapsing experimental allergic encephalomyelitis. Immunol (1995) 154:1481.
  • WEBB LMC, WALMSLEY MI, FELDMANN M: Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur.j Immunol (1996) 26:2320–2328.
  • DAIKH DI, FINCK BK, LINSLEY PS et al.: Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/ CD28 and CD40/uo39 costimulation pathways. J. Immunol (1997) 159:3104–3108.
  • DAIKH DI, WOFSY D: Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. Immunol (2001) 166:2913–2916.
  • ABRAMS JR, LEBWOHL MG, GUZZO CA et al.: CTLA4Ig-mediated blockade of T-cell co-stimulation in patients with psoriasis vulgaris. j Clin. Invest. (1999) 103:1243–1252.
  • •CTLA4Ig in psoriasis.
  • SAYEGH MH: Finally, CTLA4Ig graduates to the clinic. Clin. Invest. (1999) 103(9):1223–1225.
  • MORELAND LW, ALTEN R, VAN DEN BOSCH F et al: Costimulatory blockade in patients with rheumatoid arthritis. Arthritic Rheum. (2002) 46:1470–1479.
  • •Phase II paper.
  • HOCHBERG MC, CHANG RW, DWOSH I et al: The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritic Rheum. (1992) 35:498–502.
  • KREMER J, WESTHOVENS R, LEON M et al: A Phase IIb multi-center, randomized, double-blind, placebo controlled study to evaluate the safety and efficacy of two different doses of CTLA4Ig administered intravenously to subjects with active rheumatoid arthritis while receiving methotrexate. Arthritic Rheum. (2002) 46(9, Suppl.):S203 (Abstract 463).
  • EMERY P, WILLIAMS GR, LIT et al.: Impact on health-related quality of life following treatment with CTLA4Ig in patients with active rheumatoid arthritis using methotrexate. Arthritic Rheum. (2002) 46(9, Suppl.):S515 (Abstract 1377).
  • WEINBLATT M, SCHIFF M, GOLDMANN M et al.: A pilot, multi-center, randomized, double-blind, placebo-controlled study of a co-stimulation blocker CTLA4Ig (2 mg/kg) given monthly in combination with etanercept in active rheumatoid arthritis. Arthritic Rheum. (2002) 46(9, Suppl.):S204 (Abstract 464).
  • EMERY P, WILLIAMS GR, LIT et al.: Improvement in health-related quality of life in patients with active rheumatoid arthritis: CTLA4Ig combined with etanercept compared to etanercept plus placebo. Arthritic Rheum. (2002) 46(9, Suppl.) :S514 (Abstract 1376).

Websites

  • www.fda.gov/dockets/ac/01/briefing/ 377961.htm FDA Arthritis Advisory Committee Meeting (2002).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.